Sign in
LONA Stock Price, Chart, Stats & News
LeonaBio, Inc.
Save
32.62M
Market cap
–
Current P/E
–
Forward P/E
LONA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -125.61% |
ROE | -107.06% |
D/E | 0.03x |
Interest coverage ratio | – |
LONA valuation
P/E | – |
P/S | – |
P/B | 1.32x |
P/CF | -0.68x |
P/FCF | -0.68x |
P/OCF | -0.68x |
PEG | -0.02x |
EV multiple | -1.48x |
About
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment.
Similar securities
Based on sector and market capitalization
Report issue